Published in Oncologist on June 11, 2015
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma | NCT01952769
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321) | NCT01308294
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | NCT00658892
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol (2016) 0.86
Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Rev Anticancer Ther (2015) 0.81
Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol (2016) 0.81
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res (2015) 0.80
Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol (2016) 0.79
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst (2017) 0.78
Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy (2016) 0.78
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer (2017) 0.75
Myeloid cells in the tumor microenvironment: Role of adenosine. Oncoimmunology (2015) 0.75
CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Cancer immunotherapy comes of age. Nature (2011) 12.35
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 7.86
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
Regulatory T cells: how do they suppress immune responses? Int Immunol (2009) 3.58
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
Immunotherapy: past, present and future. Nat Med (2003) 2.62
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol (2012) 2.14
High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies? Oncology (Williston Park) (2013) 2.13
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res (2011) 2.10
Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med (2012) 2.04
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol (2013) 1.86
Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 1.75
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol (2010) 1.73
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol (2012) 1.73
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood (2010) 1.72
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol (2015) 1.66
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med (2012) 1.60
OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
Tumor immunosurveillance in human cancers. Cancer Metastasis Rev (2011) 1.48
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood (2011) 1.41
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res (2013) 1.34
Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther (2009) 1.32
Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol (2012) 1.24
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23
Autoimmunity associated with immunotherapy of cancer. Blood (2011) 1.22
Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res (2014) 1.21
Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother (2008) 1.21
Immunotherapy of cancer with 4-1BB. Mol Cancer Ther (2012) 1.19
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol (2013) 1.15
Cancer immunotherapy. Mol Oncol (2012) 1.13
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res (2013) 1.12
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res (2009) 1.12
Combination immunotherapy approaches. Ann Oncol (2012) 1.11
Evolution of end points for cancer immunotherapy trials. Ann Oncol (2012) 1.10
Interleukin 2 in cancer therapy. Curr Med Chem (2010) 1.09
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest (2014) 1.06
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys (2014) 1.03
Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol (2010) 1.02
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med (2010) 1.01
Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology (2013) 0.98
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J (2012) 0.97
Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann N Y Acad Sci (2010) 0.97
The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest (2007) 0.97
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res (2012) 0.96
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book (2013) 0.85
Real-world impact of education: treating patients with ipilimumab in a community practice setting. Cancer Manag Res (2013) 0.78